110 results on '"Lipford, J Russell"'
Search Results
2. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
3. Mercapturate pathway metabolites of sotorasib, a covalent inhibitor of KRASG12C, are associated with renal toxicity in the Sprague Dawley rat
4. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
5. A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses
6. Differential Inhibition of HIV-1 Preintegration Complexes and Purified Integrase Protein by Small Molecules
7. Quantitative measurement of the requirement of diverse protein degradation pathways in MHC class I peptide presentation
8. Prospecting for molecular glues
9. Abstract 3871: KRAS G12C mutant allele amplification drives resistance to sotorasib in vitro
10. LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant NSCLC to combined KRASG12C + MCL-1 blockade
11. Abstract 2150: LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant non-small cell lung cancers to combined KRAS G12C + MCL-1 blockade
12. Diverse alterations associated with resistance to KRAS(G12C) inhibition
13. A Systematic Interrogation of MHC Class I Peptide Presentation Identifies Constitutive and Compensatory Protein Degradation Pathways
14. Abstract 1285: In vitro characterization of sotorasib and other RAS ‘His95-groove' binders and investigation of resistance mechanisms
15. Abstract 1057: Combination of the KRASG12C inhibitor sotorasib with targeted agents improves anti-tumor efficacy in KRAS p.G12C cancer models
16. A Systematic Interrogation of MHC Class I Peptide Presentation Identifies Constitutive and Compensatory Protein Degradation Pathways
17. A putative stimulatory role for activator turnover in gene expression
18. Abstract IA20: Unlocked groove—developing covalent inhibitors of KRASG12C
19. Analysis of Polyubiquitin Conjugates Reveals That the Rpn10 Substrate Receptor Contributes to the Turnover of Multiple Proteasome Targets
20. Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
21. Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl)acetamides as Covalent Inhibitors of KRASG12C
22. Abstract 4455: Discovery of AMG 510, a first-in-human covalent inhibitor of KRASG12C for the treatment of solid tumors
23. Abstract 3090:In vivocharacterization of AMG 510 - a potent and selective KRASG12Ccovalent small molecule inhibitor in preclinical KRASG12Ccancer models
24. Abstract 4484: Discovery and in vitro characterization of AMG 510–a potent and selective covalent small-molecule inhibitor of KRASG12C
25. Abstract 4455: Discovery of AMG 510, a first-in-human covalent inhibitor of KRASG12Cfor the treatment of solid tumors
26. Abstract 3090: In vivo characterization of AMG 510 - a potent and selective KRASG12Ccovalent small molecule inhibitor in preclinical KRASG12Ccancer models
27. Nucleotide binding by the HIV-1 integrase protein in vitro
28. Discovery of (R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological Malignancies
29. Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors
30. Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitors
31. The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors
32. The discovery and optimization of aminooxadiazoles as potent Pim kinase inhibitors
33. A “Click Chemistry Platform” for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation
34. Discovery of a Covalent Inhibitor of KRASG12C(AMG 510) for the Treatment of Solid Tumors
35. Discovery of N‑(1-Acryloylazetidin-3-yl)-2-(1H‑indol-1-yl)acetamides as Covalent Inhibitors of KRASG12C.
36. Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors
37. Discovery of (R)‑8-(6-Methyl-4-oxo-1,4,5,6-tetrahydro-pyrrolo[3,4‑b]-pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)-amino)-quinazolin-4(3H)‑one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological...
38. Gal4 turnover and transcription activation
39. Discovery and Optimization of Macrocyclic Quinoxaline-pyrrolo-dihydropiperidinones as Potent Pim-1/2 Kinase Inhibitors
40. Abstract 5398: In vivo development of pan-Pim kinase small molecule inhibitors
41. Abstract 5396: Characterization of small molecule inhibitors of the PIM kinases in in vitro models of hematological malignancies
42. A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation.
43. Discovery of 1H-Pyrazol-3(2H)-ones as Potent and Selective Inhibitors of Protein Kinase R-like Endoplasmic Reticulum Kinase (PERK)
44. Unfolded Protein Response in Cancer: IRE1α Inhibition by Selective Kinase Ligands Does Not Impair Tumor Cell Viability
45. Diverse roles for ubiquitin-dependent proteolysis in transcriptional activation
46. Nucleotide Binding by the HIV-1 Integrase Protein In Vitro
47. Quantitative measurement of the requirement of diverse protein degradation pathways in MHC class I peptide presentation.
48. KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors.
49. Discovery of a Covalent Inhibitor of KRAS G12C (AMG 510) for the Treatment of Solid Tumors.
50. Discovery of N -(1-Acryloylazetidin-3-yl)-2-(1 H -indol-1-yl)acetamides as Covalent Inhibitors of KRAS G12C .
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.